Cas 1001264-89-6 AKT Inhibitors GDC-0068 Ipatasertib Breast Cancer
Cas 1001264-89-6 AKT Inhibitors GDC-0068 Ipatasertib Breast Cancer
| Product name:GDC-0068 Ipatasertib | Purity:98% min |
| CAS NO:1001264-89-6 | Solubility:DMSO: ≥ 28 mg/mL |
| Molecular Formula:C24H32ClN5O2 | Package:Package according to customer requirements |
| Molecular Weight:457.996 | Storage:Store at -20℃ |
Ipatasertib, also known as GDC-0068, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GDC-0068 binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis.
Related Products:
MK-2206 2HCl; Triciribine; PHT-427; Capivasertib; Perifosine; CCT128930; AT7867; AT13148; ONC-201; Akti-1/2; SC66; Miltefosine; GSK690693
[1]. Blake JF, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012 Sep 27;55(18):8110-27.
[2]. Lin J, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res. 2013 Apr 1;19(7):1760-72
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.